Axela, Hutman Provide Update on Multiplex Pathogen Detection System Development | GenomeWeb

Axela and Hutman Diagnostics last week announced progress in the co-development of a multiplex pathogen detection system.

The two companies first announced a deal in September that would integrate Hutman's tests on Axela's Ziplex microarray platform, enabling the firms to offer the market automated bacterial detection from uncultured blood samples and other non-culture biological samples.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.